Combined with the findings from the LUX-Lung 3 and 6 trials (Yang et al. 2016), these data indicate that dose reduction of afatinib is an effective strategy for the management of key treatment-related AEs, without negatively impacting the efficacy in patients with EGFR mutation-positive NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.